Follow-on roundup: Amicus, Arena, Alder

Rare disease company Amicus Therapeutics Inc. (NASDAQ:FOLD), autoimmune and hypertension company Arena Pharmaceuticals Inc. (NASDAQ: ARNA) and migraine play Alder BioPharmaceuticals Inc. (NASDAQ:ALDR) each priced follow-on offerings, raising a total of $525 million.

Amicus raised $225 million through the sale of 18.3 million shares at $12.25 in a follow-on underwritten by JPMorgan, Goldman Sachs, BofA Merrill Lynch and Cowen. The price is a 7% discount to Amicus' close of $13.17 on Wednesday, when it proposed after market hours to raise $225 million. Amicus dipped $0.65 to $12.52 on Thursday. The company's shares gained 26% on Tuesday after FDA cleared the way for Amicus to submit an NDA without requiring an additional Phase III trial of migalastat (AT1001) to treat Fabry's disease (see BioCentury Extra, July 11)...